

EurobioPlex FluCoSyn™

Differential diagnosis of respiratory infections
by Real-Time RT-PCR¹

SARS-CoV-2²

Flu A / Flu B

RSV A / RSV B

MADE BY
EUROBIO
SCIENTIFIC
IN FRANCE

Symptomatic patients ?
Make a quick diagnosis !*

RAPID

<1h30³

EFFECTIVE

Screening of 3 viruses
in 1 well⁴

PRACTICAL

Validated on many
thermocyclers⁴

*other viruses can cause respiratory diseases.

1. For more information, please refer to the paragraph "Introduction and intended use" of the technical sheet
2. The diagnosis of SARS-CoV-2 is based on the detection of 2 viral genes.
"Diagnostic testing for SARS-CoV-2", WHO Worldwide [11 September 2020 | COVID-19]
3. For more information, please refer to the paragraph "Procedure" of the technical sheet
4. For more information, please refer to the technical sheet

CLINICAL CONTEXT

Respiratory viruses are widespread pathogenic agents, seasonal and contagious. They mainly affect the upper and lower respiratory tracts. These infections are often zoonotic and can range from mild to more severe or even lethal form. Their genome can be single-stranded or double-stranded. The transmission is mainly through the respiratory tract in a direct way (sneezing, coughing, saliva droplets...), but also indirectly (via soiled hands, objects, food or medical equipment).^{5,6}

DIAGNOSIS

The diagnosis of RNA viruses is essentially based on the identification of the viral genome by Real-Time RT-PCR. However, there are other detection methods available such as detection by immunofluorescence or immunochromatographic antigen assays that are simple and fast to implement. These methods are available on the market, but remain less sensitive than Real-Time RT-PCR, especially in adults.^{5,6}

CHARACTERISTICS

Test principle ¹	Detection of SARS-CoV-2, RSV A/B and influenza A/B genomes
Technology	Real-Time RT-PCR
Limit of detection ⁷	15 copies/ μ L for RSV, 15 copies/ μ L for SARS-CoV2, 5 copies/ μ L for Influenza
Targeted genes ¹	RdRp gene, N gene + genomic fragments of RSV and influenza
Sample Type ¹	Nasopharyngeal aspiration
Controls included ³	Positive, negative and internal controls
Time to result ³	<1h30
Thermocyclers ⁴	Validated on many thermocyclers

PERFORMANCE

Sensitivity ⁷	> 99% (FLU A/B= 96%)	Specificity ⁷	> 99%
--------------------------	----------------------	--------------------------	-------

Reference	Description	Packaging
EBX-042	EurobioPlex FluCoSyn™ (Real-Time RT-PCR)	192 tests

5. L. Andreoletti, J. Le Goff, A. Mirand, B. Pozetto. 2018. Respiratory Syncytial Virus REMIC France SFM p719 Remic 6.2 . [09/2020]

6. B. Lina, F. Morfin, S. Van der Werf. 2018. Influenza Virus REMIC France SFM p712 Remic 6.2 . [09/2020]

7. For more information, please refer to the paragraph "Performance analysis" of the technical sheet